InMed Pharmaceuticals, Inc.’s (CSE: IN) (OTCQB: IMLFF) market traction is based on the company’s proprietary cannabinoid biosynthesis technology, one of three of its core assets and one which serves as the base for its development of its drug-development pipeline of novel therapeutics that leverage … Read More
The post CannabisNewsWire Announces Publication on Revenue Potential for Specialty Biotech … appeared first on Dagga Magazine.